Pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) will be reporting earnings tomorrow before market hours. Here’s what investors should know.
Amneal beat analysts’ revenue expectations by 3.4% last quarter, reporting revenues of $730.5 million, up 18.4% year on year. It was a mixed quarter for the company, with full-year revenue guidance exceeding analysts’ expectations but a significant miss of analysts’ full-year EPS guidance estimates.
Is Amneal a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Amneal’s revenue to grow 9.2% year on year to $720.2 million, slowing from the 18.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.15 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Amneal has missed Wall Street’s revenue estimates three times over the last two years.
Looking at Amneal’s peers in the pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Bristol-Myers Squibb’s revenues decreased 5.6% year on year, beating analysts’ expectations by 3.9%, and Merck reported a revenue decline of 1.6%, topping estimates by 1.6%. Bristol-Myers Squibb traded down 1.3% following the results while Merck was up 5.1%.
Read our full analysis of Bristol-Myers Squibb’s results here and Merck’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the pharmaceuticals stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.4% on average over the last month. Amneal is down 7.6% during the same time and is heading into earnings with an average analyst price target of $11.67 (compared to the current share price of $7.55).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
